Rumination Syndrome Market Research Report – Forecast to 2027

Rumination Syndrome Market: By Diagnosis (Esophagogastroduodenoscopy, Gastric Emptying), by Treatment (Behavior Therapy, Medication and Others), by End-User (Hospitals, Gastroenterology Clinics, Research Centers and Others) - Global Forecast till 2027

ID: MRFR/Pharma/4589-HCR | 100 Pages | Published By Rahul Gotadki on March 2023         

Rumination Syndrome Market Speak to Analyst Request a Free Sample

Rumination Syndrome Market Forecast

Rumination syndrome market is expected to grow at a CAGR of 6.1% during the forecast period. The market is majorly driven by the increasing prevalence of smoking population and rising cases of reflux disorders during pregnancy. Smoking may cause dryness of the mouth thus leading to less production of saliva, which may induce symptoms of heartburn. As saliva offsets the acid, a cigarette makes it harder for the body to guard against these acids which is some of the causes of the rumination syndrome. Additionally, factors such as increasing government and private funding to support research activities are likely to boost the market growth during the forecast period, 2018–2023.

However, the presence of misbranded and spurious drugs may hamper the growth of the market during the assessment period 2018–2023. Moreover, the presence of a number of market players and the saturation in the market have increased the introduction of many misbranded and spurious drugs. These drugs are either not effective or very low in potency which may negatively impact the market during the forecast period.

Market Segmentation

The rumination syndrome market is segmented by diagnosis, treatment, and end-user. Diagnosis is further sub-segmented into esophagogastroduodenoscopy, gastric emptying, and others.

Furthermore, on the basis of treatment, the market is segmented into behavior therapy and medication. The medication segment has been sub-segmented into proton pump inhibitors and others. Proton pump inhibitors are sub-segmented into esomeprazole, omeprazole, pantoprazole, lansoprazole, dexlansoprazole, rabeprazole, and others. Based on end-user, the market is segmented into gastroenterology clinics, hospitals, research centers, and others.

Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American rumination syndrome market is segmented into two regions, namely, North America and South America. North America is further segmented into the U.S. and Canada. Europe is further segmented into Western Europe and Eastern Europe. Western Europe consists of countries such as Germany, the U.K., France, Spain, Italy, and the rest of Western Europe.

Key Players in the Rumination Syndrome Market

Some of the key players in this market are Pfizer Inc., Valent Pharmaceuticals, Medtronic, Astra Zeneca, Eisai Co. Ltd., Takeda Pharmaceuticals, Allergan Plc, Novo Nordisk A/S, Johnson & Johnson, Bayer AG, Otsuka Pharmaceutical Co. Ltd, and others.

Regional Market Summary

According to MRFR analysis, North America holds the largest market and is mainly driven by the presence of major market players, high healthcare spending, and continuous technological development. Furthermore, established market players in the market lead to globalization by pushing new products and services into developing countries and emerging economies. South America is expected to be the fastest growing market for the American rumination syndrome market due to technologically advanced devices for diagnosis and increasing demand for treatment options of chronic diseases during the forecast period 2018–2023.

The European rumination syndrome market is expected to exhibit growth during the forecast period, 2018 to 2023 with an increasing emphasis on research and developmental activities for improvement in diagnosis and treatment methods. Moreover, Germany and the U.K. are the major contributors to the growth of the market. Additionally, increasing expenditure on healthcare by these countries in Europe also accelerates the growth of the market.

Asia Pacific is expected to grow at a faster pace during the forecast period, 2018–2023. The growth is majorly attributed to the increasing patient population in developing countries and increasing investments in the healthcare sector. For instance, India is experiencing high demand for GI and related disorder drugs. Moreover, major pharmaceutical drug manufacturers are using their technology and services to develop new drugs for GI diseases to meet the growing demand. Furthermore, healthcare in Malaysia is segmented into a government universal healthcare scheme and a private healthcare system. The private healthcare system is growing rapidly, especially, in urban areas due to increasing wealthy and middle-class population, geriatric population, urbanization, and high-quality healthcare and medicines. Thus, the rapidly growing economies of the Asia Pacific region are expected to provide vital support to the rumination syndrome market.

The Middle Eastern and African market for the rumination syndrome exhibits a steady rise with an increase in the number of healthcare facilities providing treatments of chronic conditions and the flourishing growth of the medical devices market. In the African region, the awareness about the rumination syndrome is fueling the growth of the market.  

Research Methodology

Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, technology assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.

Rumination Syndrome Market, by Diagnosis

  • Esophagogastroduodenoscopy

  • Flexible Endoscope

  • Gastric Emptying

  • CT scan

Rumination Syndrome Market, by Treatment

  • Behavior therapy

  • Medication

    • Proton pump inhibitors

      • Esomeprazole

      • Omeprazole

      • Pantoprazole

      • Lansoprazole

      • Dexlansoprazole

      • Rabeprazole

      • Others

Rumination Syndrome Market, by End-User

  • Gastroenterology Clinics

  • Hospitals

  • Research Centers

  • Others

Rumination Syndrome Market, by Region

North America

  • U.S.

  • Canada

South America


  • Western Europe

  • Germany

  • France

  • U.K.

  • Italy

  • Spain

  • Rest of Western Europe

  • Eastern Europe

Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Republic of Korea

  • Rest of Asia Pacific

Middle East and Africa

  • Middle East

  • Africa

Market Players

  • Pfizer Inc.

  • Valent Pharmaceuticals

  • Medtronic

  • Astra Zeneca

  • Eisai Co. Ltd.

  • Takeda Pharmaceuticals

  • Allergan Plc.

  • Novo Nordisk A/S

  • Johnson & Johnson

  • Bayer AG

  • Otsuka Pharmaceutical Co. Ltd.

  • Others

Intended Audience

  • Medical Device Manufacturers

  • Medical Device Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Major treatments against rumination syndrome include behavioral therapy, medication, and others.

Global rumination syndrome market is expected to exhibit a strong 6.1% CAGR over the forecast period till 2027.

The growing popularity of smoking is likely to be a major driver for the rumination syndrome market.

North America holds the largest share in the global rumination syndrome market.

Leading players in the rumination syndrome market include Medtronic, AstraZeneca, and Takeda Pharmaceuticals, among others.